Key result
Telmisartan optimizes 24-hour BP control, particularly suppressing the early morning surge in hypertension.
Why the study?
Hypertension is a major global health problem associated with increased mortality, and telmisartan is an angiotensin receptor blocker studied as monotherapy or combination therapy for its management.
Does telmisartan as a monotherapy or combined improve hypertension management in patients with hypertension?
Does telmisartan as a monotherapy or combined improve hypertension management in patients with hypertension?
This literature review discusses the efficiency of telmisartan in managing hypertension, either as monotherapy or in combination therapy.
May support telmisartan for 24-hour BP control; leaves open need for prospective RCTs confirming combination benefits.
Hypertension is considered a major health problem around the world. It’s associated with increasing risk of mortality due to its complication which has a great impact on patient’s life quality. Angiotensin Receptor Blocker has been widely used to manage hypertension, especially if diabetes coexists and the patient is less tolerable to angiotensin-converting enzyme inhibitors. In particular, telmisartan has been studied either as a monotherapy or combined with other antihypertensive agents. This study aims to understand the efficacy, safety, and tolerability of telmisartan as monotherapy or, in combination, is it superior to other agents? We used the PubMed database to search for relevant articles on the topic. Telmisartan administration showed excellent 24-hour protection against elevated BP, particularly in the early morning BP surge, which is the most expected period where cardiovascular events or strokes occur. In patients resistant to monotherapy, the use of telmisartan combinations provides better BP control compared to other agents, especially in the triple combination, where the drug's side effects are significantly decreased.
No takes yet. Share an insight, caveat, or question.
Alghamdi et al. (2021) conducted a review in Hypertension. Telmisartan vs. Other antihypertensives or placebo was evaluated. Telmisartan provides excellent 24-hour blood pressure control, particularly during the early morning surge, and offers superior efficacy and tolerability when used in combination therapies for hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: